Skip to main content

Table 1 Characteristics of studiesa

From: World-wide variation in incidence of Acinetobacter associated ventilator associated pneumonia: a meta-regression

  Multinational Europeb Mediterraneanb Asiab Middle Eastb Central & South Americab USA/Canadab Ungroupedb
Sources [ref] Additional file 1: Table S1
[S1-S4]
Additional file 1: Table S2
[S5-S37]
Additional file 1: Table S3
[S38-S57]
Additional file 1: Table S4
[S58-S64]
Additional file 1: Table S4
[S65-S73]
Additional file 1: Table S5
[S74-S81]
Additional file 1: Table S5
[S82-S96]
Additional file 1: Table S6
[S97-S100]
Number of groups 13 35 20 7 11 9 18 4
MV for >48 h for <75 %c 0 1 1 1 0 1 2 0
Trauma ICUsd 1 2 6 0 4 0 6 0
Bronchoscopic samplinge 3 18 13 1 1 1 7 1
Intervention period 1 2 0 0 1 1 1 0
Study publication year (range) 1993-2012 1988-2016 1987-2012 2001-2016 2000-2013 1995-2013 1987-2014 1987-2015
Numbers of patients per study group; median (IQR) 2082;
1029-3413
385;
145-764
194;
101-318
952;
301-16426
260;
100-724
270;
233-427
340;
277-678
174;
65-331
Duration of MV (days);
median (IQR)
6; 5-7 11; 7.4-14 8; 6.5-10.2 7.5; 6-9 8.9; 7.1-10 9.6; 7.6-10 5.5; 4–10.5 9.2; 4–10.6
VAP incidence;         
 • per 1000 ventilator days;
  o mean; f
  o 95 % CI
30 · 6;
20 · 4–40 · 7
24 · 3;
18 · 1–30 · 4
29.8 %
21 · 4–38 · 2
29 · 7;
15.9–43 · 5
34 · 0;
22.9–44 · 9
31 · 5;
19 · 3–43 · 6
26 · 7;
17 · 9–35 · 5
33 · 7;
15 · 4–51 · 9
Acinetobacter (all) VAP incidenceg         
 • per 1000 ventilator days;
  o mean; h
  o 95 % CI
4 · 2;
2 · 8–6 · 2
1 · 3;
0.7–2 · 5
3 · 5;
2.0–6 · 1
5.5;
2 · 4–12 · 8
8.8;
6 · 2–12 · 7
3 · 3;
1 · 8–6 · 2
1 · 2;
0 · 8–2 · 1
3 · 1;
1 · 9–5 · 2
Acinetobacter baumanii VAP incidence i         
 • per 1000 ventilator days;
  o mean; j
  o 95 % CI
8 · 2;
0 · 7–3 · 5
0 · 51;
0.1–0 · 9
2 · 8;
1 · 4–5 · 4
6.6;
2 · 1–20 · 1
18.0;
9 · 8–33 · 1
4 · 4;
2 · 0–10 · 0
1 · 2;
0 · 6–2 · 6
 
  1. aAbbreviations; ICU, Intensive care unit; MV; Mechanical ventilation; NA not applicable; VAP ventilator associated pneumonia; IQR, interquartile range
  2. bEurope includes France, Germany, United Kingdom, Switzerland, Sweden, Iceland, and Poland; Mediterranean includes Spain, Italy, Greece and Tunisia; Asia includes China, India, Pakistan and Bangladesh; Middle East includes Turkey, Iraq, Lebanon and Saudi Arabia; Central & South America includes Argentina, Brazil, Chile, Colombia, Cuba and Guatemala; Northern America includes USA and Canada; Ungrouped includes Australia and South Africa
  3. cStudies for which less than 75 % of patients were reported to receive more than 48 h of mechanical ventilation
  4. dTrauma ICU defined as an ICU with >50 % of patient admissions for trauma
  5. eBronchoscopic versus tracheal sampling toward the diagnosis of VAP
  6. fMean VAP incidence (per 1000 MV days) was not significantly different between the six geographic regions; p = 0.74
  7. gAcinetobacter (all) refers to Acinetobacter regardless of whether listing in the original study was as Acinetobacter species, Acinetobacter baumanii, or other speciation
  8. hMean Acinetobacter VAP incidence (per 1000 MV days) was significantly different between the six geographic regions; p = 0.003
  9. iOnly from those studies that specified Acinetobacter baumanii
  10. jMean Acinetobacter VAP incidence from studies reporting as Acinetobacter baumanii (per 1000 MV days) was significantly different between the six geographic regions; p = 0.014